Media Coverage

Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech…

Enveric Biosciences licenses its EB-002 drug candidate to MycoMedica Life Sciences, focusing on mental health treatment advancements. Enveric receives up to $62M in milestone payments and royalties, while prioritizing its…

Enveric Biosciences Inc, a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio. This latest additions bring Enveric's total to nine issued…

New preclinical results showcase EB-003’s ability to target serotonergic receptors while minimizing risks of cardiovascular and CNS side effects, advancing its potential as a non-hallucinogenic treatment for mental health disorders.…

Companies like Enveric Biosciences are taking a different approach by attempting to strip psychedelics of their hallucinogenic effects altogether. Enveric's CEO Joseph Tucker suggests that a non-hallucinogenic version of psychedelics,…

In an era where mental health disorders such as depression and anxiety are among the leading causes of disability worldwide, the search for innovative treatments is more pressing than ever.…

Enveric Biosciences ENVB recently announced that research highlighting the Company's lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N,…

Psychedelics biotech company Enveric Biosciences has presented research highlighting its lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit showing beneficial outcomes in preclinical models of anxiety and depression. EB-003…

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

Joseph Tucker, Ph.D., CEO of Enveric Biosciences, offered valuable insight into the issues spotlighted by the FDA’s decision. “The thematic challenges that came to light in the Lykos Adcomm largely…